The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) for its innovator bevacizumab (Avastin) in combination with carboplatin and paclitaxel chemotherapy, followed by Avastin alone, for the front-line treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) for its innovator bevacizumab (Avastin) in combination with carboplatin and paclitaxel chemotherapy, followed by Avastin alone, for the front-line treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Avastin, an angiogenesis inhibitor, is currently approved for treatment of 2 different forms of advanced cancer that recurred after platinum-based chemotherapy (non-squamous non—small cell lung cancer, carcinoma of the colon or rectum, and renal cell carcinoma). The FDA is expected to decide on whether to approve the new indication for Avastin by June 25, 2018.
This sBLA for Avastin, in the combination and order of treatment as specified, is based on data from the pivotal phase 3 GOG-0218 trial, which was conducted by the Gynecologic Oncology Group and published in The New England Journal of Medicine. GOG-0218 was a multicenter, randomized, double-blind, placebo-controlled phase 3 study in 1873 women with previously untreated advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who already had surgery to remove as much of the tumor as possible. Study participants were randomized to 1 of 3 treatment arms:
Women who received Avastin in combination with chemotherapy, and continued use of Avastin alone for a duration of 22 cycles, lived the longest without disease progression, with a median progression-free survival of 18.2 months compared with 12.0 months in women who received chemotherapy alone (hazard ratio, 0.64; 95% confidence interval, 0.54-0.77; P < .001).
Secondary endpoints of the study included overall survival and objective response rate. Adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications, the company said.
The sBLA seeking the new indication follows closely on the heels of the FDA’s approval of Amgen’s bevacizumab biosimilar, ABP 215 (Mvasi), the first biosimilar of Avastin approved for use in the United States. Amgen, seeking to launch its product, is currently engaged in a lawsuit against Genentech in a California district court. Amgen seeks a judgment that its biosimilar has not infringed on 27 patents covering the reference bevacizumab. When Amgen eventually brings Mvasi to the US marketplace, the biosimilar will compete for a share of substantial bevacizumab sales; Avastin was responsible for $6.75 billion in global sales for Genentech in 2016.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.